Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Arrowhead Pharmaceuticals (ARWR) stock
Learn how to easily invest in Arrowhead Pharmaceuticals stock.
Arrowhead Pharmaceuticals, Inc is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Arrowhead Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Arrowhead Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ARWR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- ARWR shares summary
- Compare share dealing platforms
- Is ARWR stock a buy or sell?
- Stock performance over time
- Can I short ARWR shares?
- Arrowhead Pharmaceuticals's financials
- How volatile are ARWR shares?
- Does Arrowhead Pharmaceuticals pay a dividend?
- Have ARWR shares ever split?
- Other common questions
Arrowhead Pharmaceuticals stock price (NASDAQ: ARWR)Use our graph to track the performance of ARWR stocks over time.
Arrowhead Pharmaceuticals shares at a glance
|Latest market close||$72.60|
|52-week range||$32.86 - $93.66|
|50-day moving average||$77.10|
|200-day moving average||$75.01|
|Wall St. target price||$89.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.09|
Buy Arrowhead Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arrowhead Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arrowhead Pharmaceuticals price performance over time
|1 week (2021-07-14)||N/A|
|1 month (2021-06-25)||-19.62%|
|3 months (2021-04-21)||N/A|
|6 months (2021-01-21)||N/A|
|1 year (2020-07-21)||N/A|
|2 years (2019-07-21)||N/A|
|3 years (2018-07-21)||N/A|
|5 years (2016-07-21)||N/A|
Is Arrowhead Pharmaceuticals under- or over-valued?
Valuing Arrowhead Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arrowhead Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arrowhead Pharmaceuticals's EBITDA
Arrowhead Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $5.9 million.
The EBITDA is a measure of a Arrowhead Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Arrowhead Pharmaceuticals financials
|Revenue TTM||$89.1 million|
|Gross profit TTM||$88 million|
|Return on assets TTM||-11.23%|
|Return on equity TTM||-23.34%|
|Market capitalisation||$7.1 billion|
TTM: trailing 12 months
Shorting Arrowhead Pharmaceuticals shares
There are currently 3.7 million Arrowhead Pharmaceuticals shares held short by investors – that's known as Arrowhead Pharmaceuticals's "short interest". This figure is 17.3% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Arrowhead Pharmaceuticals shares can be evaluated.
Arrowhead Pharmaceuticals's "short interest ratio" (SIR)
Arrowhead Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arrowhead Pharmaceuticals shares currently shorted divided by the average quantity of Arrowhead Pharmaceuticals shares traded daily (recently around 897552.19512195). Arrowhead Pharmaceuticals's SIR currently stands at 4.1. In other words for every 100,000 Arrowhead Pharmaceuticals shares traded daily on the market, roughly 4100 shares are currently held short.
However Arrowhead Pharmaceuticals's short interest can also be evaluated against the total number of Arrowhead Pharmaceuticals shares, or, against the total number of tradable Arrowhead Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arrowhead Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Arrowhead Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0366% of the tradable shares (for every 100,000 tradable Arrowhead Pharmaceuticals shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arrowhead Pharmaceuticals.
Find out more about how you can short Arrowhead Pharmaceuticals stock.
Arrowhead Pharmaceuticals share dividends
We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.
Have Arrowhead Pharmaceuticals's shares ever split?
Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.
Arrowhead Pharmaceuticals share price volatility
Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $32.86 up to $93.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 1.2546. This would suggest that Arrowhead Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.
Stocks similar to Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals in the news
7 Best ETFs to Buy That Will Make Your World a Better Place
Here is What Hedge Funds Think About Arrowhead Pharmaceuticals Inc. (ARWR)
First Week of March 2022 Options Trading For Arrowhead Pharmaceuticals
Frequently asked questionsWhat percentage of Arrowhead Pharmaceuticals is owned by insiders or institutions?
Currently 3.191% of Arrowhead Pharmaceuticals shares are held by insiders and 67.141% by institutions. How many people work for Arrowhead Pharmaceuticals?
Latest data suggests 232 work at Arrowhead Pharmaceuticals. When does the fiscal year end for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's fiscal year ends in September. Where is Arrowhead Pharmaceuticals based?
Arrowhead Pharmaceuticals's address is: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 What is Arrowhead Pharmaceuticals's ISIN number?
Arrowhead Pharmaceuticals's international securities identification number is: US04280A1007 What is Arrowhead Pharmaceuticals's CUSIP number?
Arrowhead Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 042797100
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy Hellenic Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert